Flamel Technologies, Inc

Latest News

March 8, 2010
Flamel Technologies Announces Fourth Quarter and Year-End 2009 Results

A conference call to discuss the earnings is scheduled for 8:30 AM EST on March 09, 2010.
The dial-in number (for investors in the U.S. and Canada) is 1-877-857-6173; the conference ID number is 2453008.
International investors are invited to dial 1 719-325-4888.
Webcast

March 1, 2010
Flamel Technologies Announces Projected Release Date of Fourth Quarter and Annual Results; Conference Call

December 18, 2009
Flamel Technologies Announces the Initiation of a Phase 2a Clinical Trial of Flamel's IFN-Alpha-2b XL in Patients with Chronic Hepatitis C Virus Infection

November 16, 2009
Flamel Technologies Announces Third Quarter 2009 Results; Additional New Projects; Cash Increases from $45.1 to $48.8 million
A conference call to discuss earnings is scheduled for 8:30 AM EST November 16, 2009.
The dial-in number (for investors in the U.S. and Canada) is 1-800-860-2442; the conference ID number is 435349.
International investors are invited to dial 1 412-858-4600.
Webcast

November 04, 2009
Flamel Technologies Announces Licensing Agreement with Pfizer

September 18, 2009
Flamel Technologies to Present at UBS Global Life Sciences Conference

Medusa®

A Versatile Nano Carrier for the Delivery of Native Proteins

Medusa®, a self-assembled poly-aminoacid nanoparticles system, is a versatile protein carrier for the development of novel and second-generation long-acting native protein drugs. more info

Micropump® Technologies

From Pediatric to Geriatric Uses

Controlled-release systems permitting either extended (Micropump® I) or both delayed and extended (Micropump® II) delivery of small molecule drugs.

more info

November 14, 2001 Flamel Technologies announces funded feasibilty study with a major bio-pharmaceutical company using its Medusa® technology.

October 30, 2001 Flamel Technologies announces third quarter results, loss per share of $(0.04).

October 23, 2001 Flamel Technologies S.A. announces completion of human proof of concept study for controlled-release antibiotic.

October 10, 2001 Flamel Technologies announces licensing agreement with Merck & Co., Inc..

September 27, 2001 Flamel Technologies announces negative response of French authorities on filing of Genvir® for registration.

August 24, 2001 Flamel Technologies announces the resignation of Jean Deleage as a board member.

July 30, 2001 Flamel Technologies announces second quarter and first half of 2001.

July 12, 2001 Flamel Technologies announces a feasibility study employing Medusa®; positive phase I results with Micropump ® and departure of Michael Myers.

April 30, 2001 Flamel Technologies announces first quarter results, reducing loss per share to $(0.05) on higher revenues.

March 15, 2001 Flamel Technologies announces 2000 results

January 10, 2001 Flamel Technologies announces two new Micropump® feasability studies with major pharmaceutical companies, change to NASDAQ trading symbol

January 4, 2001 Flamel Technologies to work with Connetics Corporation on new feasability study utilizing Medusa®, Flamel's patented protein delivery technology